Pharmadrug (TSE:PHRX) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
PharmaDrug has commenced a clinical study for PD-001, a patented enteric-coated cepharanthine, aimed at treating viral infections. The study will assess bioavailability and pharmacokinetics in volunteers, with the goal to improve upon the drug’s traditionally low bioavailability. Positive results could lead to Phase 2 trials and attract potential pharmaceutical partners or investors.
For further insights into TSE:PHRX stock, check out TipRanks’ Stock Analysis page.